ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: A previous study showed that p210 Bcr–Abl positive K562 cells, which are generally less sensitive to anticancer drugs, exhibited higher sensitivity to UA than non-CML cell lines such as HL-60 and U93723.